In vivo activity of the most proximal promoter of the human aldolase A ene and analysis of transcriptional control elements  by Izzo, Paola et al.
Volume 257, number 1, 75-80 FEB 07724 October 1989 
In vivo activity of the most proximal promoter of the human aldolase A 
gene and analysis of transcriptional control elements 
Paola Izzo, Paola Costanzo, Angelo Lupo, Emilia Rippa and Francesco Salvatore 
Department of Biochemistry and Medical Biotechnology, Faculty of Medicine II, University of Naples, I-80131 Naples, Italy 
Received 30 August 1989 
The genomic region upstream from exon F (exon IV) of the human aldolase A gene has been studied for its ability to direct the transcription 
of a reporter gene in vivo. Transfection experiments in human hepatoma cells (Hep 3B) followed by CAT assay, and S, mapping analysis, demon- 
strated that: (i) this region is able to drive CAT gene transcription; (ii) all the transcriptional control elements of this promoter are downstream 
from nucleotide - 384 of the longer ubiquitous RNA start site and the sequences between - 384 and - 262 play a crucial role in transcriptional 
efficiency; (iii) initiation starting points for two mRNAs exist 61 bp apart. Gel retardation and footprinting assays demonstrated the presence of 
DNA-protein complexes mainly in the region between - 384 and -262 and such ubiquitous binding factors as Spl and AP-1. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
The human aldolase A gene is a useful system with 
which to study the molecular mechanisms that regulate 
both tissue-specific and constitutive gene expression. In 
fact, using 3 putative promoter regions, multiple 
transcripts containing the same coding segment with 
alternative 5 ’ leader exons arise from the human 
aldolase A gene [l-3]. One of the alternative leader ex- 
ons is muscle specific (M), and the others (Lr, LZ and 
F) are of the ‘housekeeping’ type. The first two exons 
(Lr and Lz) are present in aldolase A mRNA, which was 
first isolated and sequenced from liver [4] and then also 
detected in lymphoblasts, muscle and spleen [2]. The 
proximal leader exon F (exon IV) has been found in two 
mRNA species of slightly different lengths that are ex- 
pressed in all human and rat tissues examined so far 
[2,3,5,6]. The putative promoter region responsible for 
the expression of the latter ubiquitous mRNAs, and the 
relative initiation sites have been suggested by struc- 
tural analysis and conventional Sr mapping and primer 
elongation experiments [2,3,5]. 
Here we demonstrate the in vivo activity of the most 
proximal promoter region and the presence of 
regulatory elements at this ubiquitous promoter. 
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Chemicals were from Sigma, Merck or Serva. Restriction enzymes, 
Td polynucleotide kinase and Ml3 primer were from Amersham In- 
ternational (UK). Deoxy- and dideoxy-nucleotides were from Phar- 
macia Inc. (Uppsala, Sweden). DNase I, poly(dI-dC) and Ea131 
exonuclease were from Boehringer, Ingelheim. Thin-layer 
chromatography paper was purchased from Macherey-Nagel, FRG. 
X-ray films were from Fuji. [“‘C]Chloramphenicol was purchased 
from NEN Du Pont (De Nemours, France). 
2.1. Plasmid construction 
The recombinant clone pA5 ‘CAT was constructed by cloning an 
EcoRI-BamHI fragment, which contains the complete 5’ region 
(3500 bp) of the human aldolase A gene, in the HindIII-SmaI sites of 
pEMBL8CAT polylinker (see fig.1). Clone pAA- includes, in the 
HindIII/SmaI site of pEMBL8CAT [7], a SmaI fragment of about 
500 bp containing 120 bp of exon F and 384 bp of its upstream 
region. Progressive deletions of pAA- (see constructs in fig.1) 
were obtained by Ba131 exonuclease. 
DNA fragments, used in bandshift and footprinting assays, were 
obtained using internal restriction sites of pAA- and cloned in the 
SmaI site of pUCl2 plasmid. 
2.2. Cell culture, DNA transfection and CAT assay 
Human hepatoma cell line (Hep 3B) [8], HeLa cells and human 
fibroblasts were grown as monolayers in DMEM medium sup- 
plemented with 10% (v/v) fetal calf serum. Cells were plated at a den- 
sity of 1 x lo6 per 10 cm tissue culture plate and were transfected by 
the calcium phosphate method [9]. 20rg of supercoiled plasmid 
DNA was added to each plate and 2pg of pSVfi globin were 
cotransfected as internal marker. CEll extracts were prepared as 
described by Gorman et al. [lo]. 
For the CAT assay [lo], we used 100 cg of protein extract, 0.2 pCi 
[‘4C]chloramphenicol, 20 ~1 of 4 M acetyl-CoA, in Tris 250 mM, in 
a total volume of 150 ~1. After incubation at 37°C for 1 h, the reac- 
tion was stopped with ethylacetate. The acetylated and unreacted 
forms, separated by thin-layer chromatography, were excised and 
counted in a scintillation counter. 
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2.3. RNA extraction and SI mapping assay 
Total RNA was extracted by the guanidine thiocyanate procedure 
11 I]. In the S1 mapping assays 112) with total RNA extracted from 
transfected cells, a Kpnl-EcoRI fragment, including about 500 bp of 
the human aldolase A gene and 220 bp of the CAT gene, was cloned 
in M13mp19 and used as probe (see fig.2). For the cotransfected SV@ 
globin internal marker, a BarnHI fragment, including about 700 bp 
of the/? globin gene cloned downstream the SV40 promoter, was used 
as probe (see fig.2). 
2.4. Preparation of nlrclear extracts and gel retardation assay 
Nuclear protein extracts were prepared from HeLa cells grown in 
suspension to a density of approximately 5 x lo5 cells/ml, according 
to Shapiro et al. [13]. For the gel retardation assays HeLa cell nuclear 
extracts (about 10 gg of protein) were incubated in a total volume of 
20 ~1 containing: 10000 cpm end-iabelled probe, 8% Ficoll, 20 mM 
Hepes (pH 7.9), 50 mM KCl, 1 mM EDTA, 0.5 mM DTT, lOolo 
glycerol, 2 mM MgClz, 4 mM spermidine, 3 pg poly(dI-dC) and 
0.5 pg salmon sperm DNA. Samples were incubated at 25°C for 
10 min. Free DNA and DNA-protein complexes were resolved on a 
4% polyacrylamide gel in 0.5 x TBE (1 x TBE is: 90 mM Tris- 
borate, 90 mM boric acid, 4 mM EDTA). After electrophoresis at 
10 V/m in a cold room, the gel was dried and autoradiographed. 
For competition experiments, from lo- to lOO-fold molar excess of 
competitor DNA was added to the reaction. 
2.5. DiVase i ~oo~pr~n~in~ 
DNase 1 footprint assays were performed as described by Licht- 
Steiner et al. [14]. An end-labelled DNA fragment (20000 cpm) was 
added to a 20~1 reaction (final volume), containing 25 mM Hepes 
(pH 7.6), 60 mM KCI, 7.5% (v/v) glycerol, 0.1 mM EDTA, 
0.75 mM DTT, 5 mM MgCl2 and 1 pg double-stranded poly(dI-dC) 
competitor DNA. Nuclear extract was added last and, after 90 min 
in ice, DNase I (1~1) and 100 pg/ml BSA were added to the reactions. 
After 5 min in ice, the reactions were stopped, extracted and loaded 
onto 8% polyacrylamide 10 M urea sequencing el, as previously 
described [14]. 
3. RESULTS AND DISCUSSION 
3.1. Transient expression analysis of the proximal 
promoter region 
A restriction fragment of about 3500 bp, which in- 
A 
eludes the 5 ’ flanking region of the human aldolase A 
gene, was cloned in pEMBL&CAT, in the correct 5 ’ to 
3 ’ orientation, to yield the recombinant pfasmid 
PAS’-CAT (fig.lA). The recombinant plasmid 
pAA- contains 120 bp of exon F and 384 bp of its 
upstream putative promoter region. Bal3 1 exonuclease 
was used to delete the pAA- clone to produce 
pAA-262, pAA-178, pAA- recombinant clones 
(fig. IA). 
These constructs were assessed for expression of 
CAT enzyme activity after transient transfections into 
human hepatoma cells (Hep 3B). Fig.lB shows the 
CAT activity of each of the constructs depicted in 
fig.lA. The CAT activity observed with both 
pA5 ‘-CAT and pAA- was very high: 80-88~a, ex- 
pressed as a relative ratio to the activity of pSV2-CAT 
that contains the promoter and enhancer of SV40. 
These data demonstrate, for the first time, the ex- 
istence of functional promoter sequences upstream 
from exon F, and provide indirect evidence for the ex- 
istence of other functional distal promoters. Moreover, 
the 384 bp upstream from exon F contain all the 
elements necessary for the optimal activity of this prox- 
imal ubiquitous promoter; sequences further upstream 
appear to be unrelated to this activity. 
A deletion of about 122 bp (clone pAA-262), and 
another larger deletion (pAA-178) decreased promoter 
activity by about 66010; a larger deletion producing the 
pAA- construct further decreased the promoter ac- 
tivity. These results indicate that the region between 
-384 and -262 contains sequences crucial for efficient 
promoter activity, whereas less efficient cis-elements 
are contained in the region between - 178 and + 1. No 
regulatory elements were found between -262 and 
-178. The same results were obtained in transfected 
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Fig.1. (A) Map of plasmids containing deletions of the 5’ flanking region of the human aldolase A gene linked to the CAT gene. Lt, L2, M and 
F are the non-coding exons of the gene. (B) Expression of CAT activity in Hep3B cells transfected with deletion plasmids. The values shown 
are the average of 4 independent experiments. CAT activities are expressed as relative ratio to pSV2-CAT activity. 
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HeLa cells and human fibroblasts (data not shown). 
Therefore, these findings are further confirmation of 
the ubiquitous expression of the proximal promoter 
region of the human aldolase A gene. 
Fig.2 shows an Sr nuclease analysis on total RNA 
isolated from Hep 3B cells transfected with the recom- 
binant clones pAA- and pAA-262. Two protected 
fragments of about 370 bp and 310 bp, respectively, 
were observed. The initiation sites of these transcripts 
correspond to those previously indicated by structural 
analysis, Si mapping and primer elongation ex- 
periments as being the starting points for the ubi- 
quitous mRNAs [3]_ 
The deletion of 122 bp (clone pi-262), which caus- 
ed CAT activity to decrease by about 66% compared 
with clone pAA-384, affects the transcriptions effi- 
ciency of both mRNAs. As shown in fig.2, lane 2, the 
level of the two transcripts decreases to the same extent, 
whereas the cotransfected ,& globin transcript showed 
the same efficiency in both transfection experiments 
(fig.2, lanes I and 2). This suggests that the region bet- 
ween -384 and -262 contains cis-elements essential 
also for the transcriptional modulation of both ubi- 
quitous mRNAs. 
3.2. Binding of ubiquitous trans-acting factors to 
regulatory seqerences 
Gel retardation and footprinting assays were per- 
formed to detect and identify nuclear factors that in- 
teract with the essential proximal (downstream 
nucleotide -384) promoter region of the human 
aldolase A gene. Using internal restriction en- 
donuclease sites, several small fragments of the region 
between -384 and +1 were cloned in the SmaI site of 
plasmid pUC12. Fig.3A shows a scheme of these 
subclones. 
Nuclear extracts from HeLa cells were tested for 
DNA-protein binding using 5 ’ end&belled probes, 
After electrophoresis on low-ionic strength 4% 
acrylamide gels, several retarded bands were detected 
for each probe ffig.3, lane 2, B-E). To test the 
specificity of the binding, competition experiments 
were performed in the presence of IO-, 50- and IOO-fold 
molar excess of either alien DNA fragments (ferritin 
DNA, etc.; data not shown) or the same unlabelled pro- 
bes (fig.3, lanes 3-5 in panels B and D). Several specific 
DNA-protein complexes were detected for each probe 
used; no competition was found in the presence of alien 
non-specific DNA. 
Sequence analysis of the region upstream from exon 
F indicates the presence of several Spl binding sites (see 
fig.4). To determine whether Spl factors were 
specifically responsible for the DNA-protein interac- 
tions observed (fig.3B and D), competition experiments 
were performed using as competitor a SphI-NcoI DNA 
fragment of about 90 bp of the SV40 promoter region 
containing six Sp 1 binding sites [I 5 J. With the pFH1 
M 123 
- Ald.Al 
- Ald.A2 
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t I 
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Fig.2. Sr mapping of the RNAs extracted from IIep3B cells 
transfected with pAA- (lane 1) and ~AA-262 (lane 2). In lane 3, 
E. coii RNA was used as negative control. In all transfection 
experiments (lanes 1 and 2) the SVfi globin plasmid was used as an 
internal control. The arrows indicate the positions of the aldolase A 
and fl globin protected bands. The lower part shows the position of 
the probes (thin lines) and that of protected bands (solid bars) with 
respect to the CAT and +9 globin transcription units. The arrows 
indicate the two initiation transcription sites of ubiquitous aldotase A 
mRNAs. 
probe all the specific DNA-protein complexes observed 
were competed for by the SphI-NcoI DNA fragment 
(fig.3C). The pFH6 probe, which includes the region 
essential for promoter activity, revealed two specific 
major complexes (fig.3D). The upper band was effi- 
ciently competed for by the 5‘phI-Z?coI DNA fragment 
of the SV40 promoter (fig.3E), whereas the lower 
specific band was unaffected. This indicates that 
nuclear factors other than Spl could be involved in the 
DNA-protein complex interaction seen in the lower 
band. 
Furthermore, the SphI-NcoI DNA fragment also 
competed with the pFH2 probe for binding with 2 out 
77 
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Fig.3. (A) Schematic representation of subclones used in the bandsbift assay. In the top line is shown the proximal promoter egion of the human 
aldolase A gene. The open bar represents about 80 bp of exon IV. The arrows indicate the two initiation transcription sites of ubiquitous mRNAs. 
Small fragments (DS 1, pFH5, pFH6, pFH 1, pFH2) obtained with HueIII, DdeI and Sau3A restriction enzymes were cloned in the SmaI site of 
pUC12 and the resultant plasmids were used to generate nd-labelled probes. (B) Bandshift assay of the clone pFH1. Lane 2 shows the presence 
of DNA-protein complexes. The results shown in lanes 3, 4, 5 were obtained with a IO-, 50- and MO-fold molar excess of unlabelled pFHl as 
competitor: the arrows indicate complexes that are affected by the competitor DNA. (Cc) Competition analysis of the pFH1 probe by a lo-, 50- 
and lOO-fold molar excess (lanes 3, 4 and 5, respectively) of the SpM-NcoI fragment of SV40 promoter element. Lane 2 = control without 
competitor. (D) Gel mobility assay with the pFH6 probe. The DNA-protein complexes are shown in lane 2. The results shown in lanes 3, 4 and 
5 were obtained with a lo-, 50- and lOO-fold molar excess of unlabelled pFH6 fragment as competitor; the arrows indicate complexes which are 
affected by competitor DNA. (E) Competition analysis of the pFH6 probe with a lo-, 50- and lOO-fold molar excess (lanes 3, 4 and 5) of the 
SphI-NcoI fragment of SV40 promoter element. Lane 2 = control without competitor. Lane 1 from B to E = probes alone. 
of 3 complexes (data not shown). This suggests that the 
third complex could involve TATA-like binding fac- 
tors, located at the 3’ end of the pFH2 fragment (see 
fig.3A). 
3.3. Localization of DNA-protein complexes aiong the 
promoter region 
To localize the position of the DNA-protein com- 
plexes, the pFH6 DNA probe (fig.3A) was used in 
DNase I footprinting analyses (see fig.5). Two pro- 
tected regions were observed in the upper strand (lanes 
l-4) between -334 and -311 (A region), and between 
-309 and -285 (B region). In the iower strand (lanes 
5-8) the protected regions were found between -258 
and -292 (A’ region), and between -290 and -303 
(B’ region). Since the DNA fragments protected by the 
DNase I cleavage are very long on both strands, the 
binding of various factors may be inferred. 
. . . 
CGCTGCAGCCGCCAACACCGGAAGCTGC~CCCCCGGCCGCGCCCGCTCCCCCTGGGAGGCC~CTCAGC~CCTTCCTTTCCCACTTTTCCATCCGCGTCCTCCACTTCCCCGTTCCG 2400 
EE~TC~CCCA~TGCC~CA~CTGG~~C~CG~C~~*G~GCC~~G~~AGGCTGGGGG~GGAGCAG~G~AGGG~CCTAG~GACC~GCGGGA~G~GGT~CGAGTCA~GT~~GA 2520 
. . . . . . . ..*.. . . . . . . 
GM;GCCTGGGGAGGGATCCTCTTCTCGGCGCCCGCCCCTTCCTAGCGCCGCCTCTCGGCT~CTCTCGGG~CGGCCCGTAGCCCAGTCCGTCGCCTGCCATTGGACGCCCCCCCCTCCT 2660 
. . . . . . 4 . . . . . . 
CGT~GG~GCTCGCCGGAGGGCGGACTffiTGC~~~CG~CGCCGCC~CCGC~GCACcGCCTCCTGCGCCGCCC~CCGAGG~~TC~CTGCG~CCTCTCG 2760 
& 
GMCGCGCCGCAC~GGGGTCCTGGTGACGAGTCCCGCGTTCTCTCC~G~TCCACTCGCCAGCCCGCCGCCCTCTGCCCCCGCACCCTCCACACCCGCCCCTCTCCTGTGCCAGGTGA 2880 
Fig.4. Sequence of the human aldolase A gene including exon F (exon IV) and its upstream region. The two transcription start sites (+l and 
+61) are indicated by arrowheads. The 176 nucleotides including exon F are underlined. Dots indicate the Spl binding sites and triangles the 
Apl binding site. The TTTAAAA sequence is boxed. 
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Strand 
1234ACGT 5678 
-334 A B - 258 
, I, I 
CCGCGTCCTCCICTTCCCCGTT~~~~~~TCCCCC~TlG~~~~C~llC~~~C:~~~::xCGGCGCCCC~~CCGGCC 
GGCGCAGGA~~~G~AGGGGC~~GGCGGG~G~GGGl~~CGGTlGl~~G~CCG~CTC~GlGCCGCGGGGlCTCGGCCGG 
I , 
B’ A’ 
Fig.5. DNase 1 footprinting assay. pFH6 (see fig.3, panel A) was used as probe: it was 5’ end&belled on the upper (lanes l-4) or on the lower 
(lanes f-8) DNA strand. Lanes 1 and 5 show DNase 1 digested probe in the absence of cell extract. The results shown in lanes 2 and 6, 3 and 
7, 4 and 8 were obtained with 100, 200 and 4OOcg of DNase I, respectively, in the presence of 20,ug of HeLa cell nuclear extract. ACGT is a 
Sanger sequence ladder. Brackets show the footprint regions. The location of footprints together with the nucleotide sequence of the pFH6 
segment is shown in the lower part. Brackets above and below the sequence indicate the regions of footprints on the upper and lower strands, 
respectiveiy. Filled circles represent he nucleotides involved in the Spl binding site. Open circles indicate the homology with the sequence motif 
of the NFl binding site. Triangles show the sequence motif of AP-1 binding site. 
DNA sequence analysis of clone pFH6 showed a 
canonical Spl binding site [i 51, a consensus sequence 
for the nuclear factor AP-I [I61 and high homology 
with the sequence recognized by the NFl-like factor 
[17] (see fig.4 and the bottom of fig.5). 
These nuclear factors are ubiquitous proteins and are 
probably responsible for the constitutive expression of 
many genes [ 18,191. Moreover, the recognition se- 
quences for Spl, AP-1 and NFl are adjacent suggesting 
that these factors could act in conjunction to modulate 
transcription [20,21]. Therefore, the binding of Spl 
factors and presumably also of AP-1 and NFl in the 5’ 
region upstream exon IV could account for the con- 
stitutive expression and the modulation of transcription 
of the human aldolase A gene. However, the much 
longer DNA stretch protected in footprinting assay 
analysis suggests the possible existence of other protein- 
interacting factors besides the above-mentioned ubi- 
quitous ones. 
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